Technology ID
TAB-4945
Innovations in Peptide Delivery and Immune Activation
E-Numbers
E-137-2018-0
Lead Inventor
Lynn, Geoffrey
Lead IC
NIAID
Co-Inventors
Ishizuka, Andrew
ICs
NIAID
Applications
Vaccines
Therapeutics
Diagnostics
Therapeutic Areas
Respiratory
Rare/Neglected Diseases
Oncology
Infectious Disease
Development Stages
Discovery
Research Products
Human Cell Lines
Antibodies
This innovative technology centers on advanced peptide-based vaccine formulations that aim to significantly boost T cell-mediated immune responses. The core of this invention is the strategic conjugation of modified peptides with polymers attached to immunostimulants, a design poised to enhance the efficacy of vaccines. This approach not only promises to refine the manufacturing process, making it more efficient but also aims to augment the generation of immune responses, potentially leading to superior vaccine performance against various pathogens.
Commercial Applications
The versatile nature of this peptide-based vaccine platform has vast potential applications, ranging from infectious diseases to personalized medicine. It can be tailored to combat emerging pathogens by quickly adapting the peptide sequences without altering the manufacturing process. This makes it invaluable for rapid response to epidemic threats. Moreover, its ability to generate robust T cell responses positions it as a promising candidate for cancer vaccines, where cellular immunity is crucial. The technology could also be extended to allergy treatments, auto-immune conditions, and as a tool in therapeutic vaccines, potentially revolutionizing the approach to immunotherapy and vaccine development across various health conditions.
Competitive Advantages
The cutting-edge peptide-based vaccine technology stands out in the competitive landscape for its ability to induce potent T cell responses irrespective of the antigen's peptide sequence. This platform’s versatility is underpinned by its novel polymeric conjugate system that ensures consistent and enhanced immunogenicity. The conjugation technique employed not only simplifies the manufacturing process, enabling scalability, but also stabilizes the vaccine, leading to a potentially broader application against a wide array of pathogens. Additionally, the modification of peptides linked to polymers and immunostimulants is an innovative step that could result in stronger and more durable immune responses, offering a significant edge over existing vaccine technologies.
Licensing Contact: